Key result
ANGPTL3 was upregulated in 60% of primary OSCCs, correlating with larger tumor size and significantly lower overall survival in patients with T3/T4 tumors (P<0.05).
Population
OSCC-derived cell lines (n = 8) and primary oral squamous cell carcinomas (OSCCs) (n = 109)
Comparison
ANGPTL3 knockdown vs Normal counterparts and control-cell xenografts
Design
Preclinical
Authors
Loading...
May inform OSCC prognostication; leaves open therapeutic targeting pending prospective validation.
p-value: p=<0.05
ANGPTL3 is upregulated in oral squamous cell carcinoma and promotes tumor growth via the ERK/MAPK pathway, suggesting it as a potential diagnostic and therapeutic target.
Koyama et al. (2015) studied Oral squamous cell carcinoma (OSCC) (n=109). ANGPTL3 expression vs. Normal counterparts and ANGPTL3-negative tumors was evaluated on ANGPTL3 upregulation in primary OSCCs compared to normal counterparts (p=<0.05). ANGPTL3 was upregulated in 60% of primary OSCCs, correlating with larger tumor size and significantly lower overall survival in patients with T3/T4 tumors (P<0.05).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: